Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4438222 | 0.71 | BRD4 (0.39) | KDM4EALDH1A1HPGDNPSR1KMT2A | |
| SCHEMBL718222 | 0.71 | ALDH1A1 (0.41) | CTSVCTSLKDM4EALDH1A1HPGD | |
| SCHEMBL542790 | 0.70 | NPC1 (0.42) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL3172556 | 0.69 | MDM2 (0.34) | KDM4EMAPTNPC1RAB9A | |
| SCHEMBL4309887 | 0.67 | PARP1 (0.36) | KDM4EALDH1A1HPGDNPSR1KMT2A | |
| SCHEMBL6992376 | 0.66 | ESR1 (0.47) | ALDH1A1HPGDPOLBKMT2AMEN1 | |
| SCHEMBL5492669 | 0.66 | BCHE (0.40) | KDM4EALDH1A1ALOX15HSD17B10TDP1 | |
| SCHEMBL3835052 | 0.66 | CNR1 (0.33) | ALDH1A1HSD17B10TUBB4ATUBBTUBA3C | |
| SCHEMBL1879217 | 0.66 | NR4A2 (0.47) | CTSVCTSLKDM4EALDH1A1NPSR1 | |
| SCHEMBL14977497 | 0.66 | HSD17B10 (0.40) | KDM4EALDH1A1HPGDMMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6107512-A | Process for making optically active α-amino ketones and selected novel optically active α-amino ketones | MONSANTO COMPANY (US) | 2000-08-22 | — | — | US | claimed |
| CN-115516012-A | Novel synthesis method and application of chitosan derivative | 诺和席卓股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-1866306-B1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| WO-2008117050-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| EP-1866306-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | Nycomed GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103255-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| US-4808503-A | SENSITIVITY, DURABILITY | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NOS2, NOS1, ARG1 | CTSV 4587/4885CTSL 3339/4885KDM4E 2894/4885 |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NOS2, NOS1, ARG1 | CTSV 4587/4885CTSL 3339/4885KDM4E 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.